ModernaTX Betacoronavirus mRNA Vaccine Lipid Nanoparticle Patent Application
Summary
USPTO published patent application US20260097110A1 by ModernaTX, Inc. for betacoronavirus mRNA vaccines formulated in lipid nanoparticles. The application covers RNA vaccines, combination vaccines, and methods of using the vaccines and compositions. The filing was submitted December 5, 2025, with inventors Giuseppe Ciarametta and Sunny Himansu.
What changed
USPTO published patent application US20260097110A1 by ModernaTX, Inc. on April 9, 2026. The application discloses mRNA betacoronavirus vaccines formulated in lipid nanoparticles, along with combination vaccines and methods of use. The application covers CPC classifications spanning coronavirus antigens (A61K 39/215), spike proteins, and vaccine formulations.
Affected parties including pharmaceutical companies, biotech firms, and vaccine developers should monitor this publication for competitive intelligence purposes. The patent claims, if granted, would cover lipid nanoparticle-encapsulated mRNA vaccines for betacoronaviruses. This publication does not impose compliance obligations but signals ModTX's continued investment in coronavirus vaccine IP.
What to do next
- Monitor for patent prosecution updates
- Review claims for competitive intelligence
- Assess IP landscape for mRNA vaccine development
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BETACORONAVIRUS mRNA VACCINES
Application US20260097110A1 Kind: A1 Apr 09, 2026
Assignee
ModernaTX, Inc.
Inventors
Giuseppe Ciaramella, Sunny Himansu
Abstract
The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.
CPC Classifications
A61K 39/12 A61K 39/155 A61K 39/215 A61P 11/00 A61P 31/14 C07K 16/10 C07K 16/102 C07K 16/11 A61K 2039/53 A61K 2039/55511 A61K 2039/55555 A61K 2039/6018 A61K 2039/70 C07K 2317/76 C12N 2760/18034 C12N 2760/18334 C12N 2760/18434 C12N 2760/18534 C12N 2760/18634 C12N 2770/20034 Y02A 50/30
Filing Date
2025-12-05
Application No.
19410927
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.